ARDS News and Press, Aridis Pharmaceuticals Inc. From 07/13/21

CIPhotos/iStock via Getty Images Shares of Aridis Pharmaceuticals ([[ARDS]] -18.5%) are down sharply in afternoon trading, a day after shares surged following the release of encouraging preclinical data for its COVID-19 antibody cocktail. In an animal model, AR-712 was effective in neutralizi...

Gainers: Allied Healthcare Products (AHPI) +107%, SCWorx (WORX) +32%, Longboard Pharmaceuticals (LBPH) +18%, Dynatronics (DYNT) +14%, Shineco (TYHT) +13%.Losers: Meridian Bioscience (VIVO) -18%, Aridis Pharmaceuticals (ARDS) -17%, Simulat...

ClaudioVentrella/iStock via Getty Images Aridis Pharmaceuticals ("ARDS") says an animal model demonstrated that its COVID-19 monoclonal antibody ("mAb") cocktail, AR-712, was effective at neutralizing the delta variant. AR-712, designed for inhaled delivery, is a combination of two fully huma...

Aridis Pharmaceuticals COVID mAb AR-712 Neutralizes SARS-CoV-2 Delta Variant Texas Biomedical Research Institute and Aridis' data confirmed AR-712 binds to and neutralizes the Delta variant of SARS-CoV-2 virus Binding analysis projects the ability of AR-712 to bind to all va...

Bristol Myers Squibb (BMY) announces that the EMA's Committee for Medicinal Products for Human Use ((CHMP)) has recommended granting Conditional Marketing Authorization for Abecma (idecabtagene vicleucel; ide-cel), the company’s BCMA-directed chimeric antigen receptor ((CAR)) T cell im...

Citius Pharmaceuticals, Inc. (NASDAQ: CTXR) finds itself up over 15% going into Tuesday’s market close after the Company announced that Dr. John Laffey, a leading scholar in Acute Respiratory Distress Syndrome (ARDS) and the use of cutting-edge therapies to treat acute lung...

Aridis Pharmaceuticals (ARDS): Q1 GAAP EPS of -$0.77 misses by $0.17.Total cash and cash equivalents as of March 31, 2021 were $10.5 million. The Company completed a registered direct financing in March 2021 and received gross proceeds of approximately $7.0 million.Press Release For further...

Aridis Pharmaceuticals Announces First Quarter 2021 Results PR Newswire LOS GATOS, Calif. , May 11, 2021 /PRNewswire/ -- Aridis Pharmaceuticals, Inc. (Nasdaq: ARDS), a biopharmaceutical company focused on the discovery and development of novel anti-infective...

Aridis Pharmaceuticals Announces 2020 Fourth Quarter and Year-End Financial Results and Business Update PR Newswire LOS GATOS, Calif. , March 30, 2021 /PRNewswire/ -- Aridis Pharmaceuticals, Inc. (Nasdaq: ARDS), a biopharmaceutical company focused on the discover...

Aridis Pharmaceuticals Interview to Air on Bloomberg Television U.S. on the RedChip Money Report® PR Newswire LOS GATOS, Calif. , March 26, 2021 /PRNewswire/ -- Aridis Pharmaceuticals, Inc. (Nasdaq: ARDS), a biopharmaceutical company focused on the disc...